Pioneering AT MicroProtect technology to combat Covid-19 and microbiological contamination, developed by a consortium led by BLC3, will be installed, for the first time in the world, at Generis Farmacêutica facility in Lisbon.
In a statement, BLC3 President João Nunes stated that the AT MicroProtect technique to combat Covid-19 and microbiological contamination will be implemented in partnership with Generis Farmacêutica, in their Lisbon industrial unit, with the “objective of making the unit safer for its employees.”
This innovative technology “manages to inactivate, in one minute, 99.97% of the particles of SARS-CoV-2 virus [which causes Covid-19 disease] in the air. In addition, this technology is suitable for use against other microorganisms, such as Mycobacterium tuberculosis (responsible for the disease of Tuberculosis) and even multi-resistant bacteria E. Coli and Satphycoccus Aureus, which are the source of serious contamination problems in health units, such as hospitals.”
Based on the basis and vision of combating microbiological contamination, the new technology and concept is not only suitable for use in the current pandemic (SARS-CoV-2 virus), but for future pandemics and even for the current contamination problems caused by multi-resistant bacteria and viruses. For example, in terms of scientific results, “in one minute, only 5 of the 16,982 SARS-CoV-2 virus particles tested remained ‘active’, giving a success rate of 99.97%. And after five and fifteen minute trials 100% of the particles were destroyed. The tests were repeated twenty-seven times to ensure accuracy.
Generis, “the leading company in Portugal in the generic medicine market and part of one of the largest global groups in the sector – Aurobindo – faces, like the whole industry, unprecedented challenges in maintaining its activity while ensuring the safety of its employees.”
